These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8945704)

  • 41. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
    Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
    J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New concepts: vaccines.
    Rapp F
    Gynecol Oncol; 1981 Oct; 12(2 Pt 2):S341-4. PubMed ID: 6273265
    [No Abstract]   [Full Text] [Related]  

  • 44. Immune response to a DNA free herpes simplex vaccine in man.
    Cappel R; Sprecher S; Rickaert F; de Cuyper F
    Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of a nucleic acid free herpetic subunit vaccine.
    Cappel R; de Cuyper F; Rickaert F
    Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mechanism of specific vaccine therapy in ocular herpes simplex].
    Shubladze AK; Zaĭtseva NS; Maevskaia TM; Cheglakov IuA; Murav'eva TV
    Vopr Virusol; 1978; (1):63-8. PubMed ID: 206026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
    JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for vaccines for herpes simplex viruses.
    Berman PW
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):226-30. PubMed ID: 2828443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing neonatal herpes--current strategies.
    Gibbs RS; Mead PB
    N Engl J Med; 1992 Apr; 326(14):946-7. PubMed ID: 1311801
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
    Benda R; Dbalý V
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
    [No Abstract]   [Full Text] [Related]  

  • 54. Herpes simplex virus vaccine workshop. Bethesda, Maryland, 31 July- 1 August 1989.
    Rev Infect Dis; 1991; 13 Suppl 11():S891-979. PubMed ID: 1664122
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical studies with herpes simplex virus type 2 Curtis strain vaccine.
    Corey L
    Rev Infect Dis; 1991; 13 Suppl 11():S904-5. PubMed ID: 1664125
    [No Abstract]   [Full Text] [Related]  

  • 56. [Therapy of recurrent Herpes simplex].
    Söltz-Szöts J
    Z Haut Geschlechtskr; 1971 Apr; 46(8):267-72. PubMed ID: 4324186
    [No Abstract]   [Full Text] [Related]  

  • 57. Prospects for a vaccine against herpes simplex virus types 1 and 2.
    Dix RD
    Prog Med Virol; 1987; 34():89-128. PubMed ID: 2821579
    [No Abstract]   [Full Text] [Related]  

  • 58. Animal studies on the efficacy of an inactivated herpes simplex virus vaccine against recurrent herpes infection.
    Scriba M
    Infection; 1978; 6(3):137-9. PubMed ID: 210127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
    Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
    J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herpes simplex vaccines.
    Hilleman MR
    Cancer Res; 1976 Feb; 36(2 pt 2):857-8. PubMed ID: 56228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.